LGVN Q2 2025 Earnings — Longeveron Inc. Revenue & Financial Results | Market Cap Arena

LGVNLongeveron Inc.

$20M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$316,000-32.5% YoY

Gross Profit

$146,00046.2% margin

Operating Income

-$5M-1707.9% margin

Net Income

-$5M-1591.1% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

-17.1%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$513,000

Balance Sheet

Total Assets

$17M

Total Liabilities

$4M

Stockholders' Equity

$13M

Cash & Equivalents

$10M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$316,000	$468,000	-32.5%
Gross Profit	$146,000	$344,000	-57.6%
Operating Income	-$5M	-$4M	-54.2%
Net Income	-$5M	-$3M	-47.3%